Gibson Dunn has advised Avere Therapeutics. Sidley Austin has advised NextCure. Avere Therapeutics, Inc., a privately-held biotechnology company, and NextCure, Inc. (Nasdaq:NXTC), a clinical-stage biopharmaceutical company,...
Avere Therapeutics and NextCure Announce Merger with $320 Million Private Placement
Pharvaris Prices $115 Million Underwritten Offering of Ordinary Shares
Kirkland & Ellis LLP and NautaDutilh N.V. have advised Pharvaris N.V. Sidley Austin LLP and Loyens & Loeff N.V. have advised the underwriters. Pharvaris N.V. (Nasdaq:...
Obsidian Therapeutics and Galera Therapeutics Announce $350 Million Merger and Private Placement
Goodwin Procter LLP has advised Obsidian Therapeutics. Sidley Austin LLP has advised Galera Therapeutics. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. has advised the placement...
Pharvaris Announces US$201.2 Million Public Offering of Shares and Pre-Funded Warrants
NautaDutilh N.V. and Kirkland & Ellis LLP have advised Pharvaris N.V. on the offering, and Sidley Austin LLP and Loyens & Loeff N.V. have advised underwriters....
BigHat Biosciences’ Collaboration with Eli Lilly and Company
Sidley Austin represented BigHat Biosciences in the transaction. BigHat Biosciences (BigHat), a biotechnology company with a machine learning (ML)-guided antibody discovery and development platform, announced a...
AdvanCell’s Collaboration with Eli Lilly and Company
Sidley Austin represented AdvanCell in the transaction, and Kirkland & Ellis represented Eli Lilly and Company. AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies,...
BigHat Biosciences’ Licensing Collaboration With Synaffix B.V.
Sidley Austin represented BigHat Biosciences, Inc. in the transaction. BigHat Biosciences, Inc. (“BigHat”), announced a licensing collaboration with Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN). BigHat’s...
BigHat Biosciences’ Collaboration with Janssen Biotech
Sidley Austin represented BigHat Biosciences in the transaction. BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced its collaboration...
Novo Nordisk’s Partnership with Evotec SE to Launch Translational Drug Discovery Accelerator
Sidley Austin LLP represented Novo Nordisk Inc. in the matter. Novo Nordisk (NYSE: NVO) announced its collaboration with Evotec SE (NASDAQ: EVO) to launch LAB eN² (pronounced Lab...
Tyra Biosciences’ $172.8 Million Initial Public Offering
Latham & Watkins represented Tyra Biosciences in the offering while Sidley advised the underwriters. Tyra Biosciences, Inc. has announced the pricing of its upsized initial public offering of...
Interius BioTherapeutics’ US$76 Million Series A financing.
Sidley Austin LLP advised Interius BioTherapeutics on the deal. Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene...